As for Imipenem-Cilastatin pills (Merck Sharp & Dohme Corp, U.S.A.), sensitivity and negative forecasts as 93.1% and 78.7% and 88.2% and, respectively, a 68.5%, respectively.
As for drugs Imipenem-Cilastatin (Merck Sharp & Dohme Corp, USA) sensitivity and negative predictive value was 93.1% and 78.7% respectively and 88.2% and 68.5% respectively.
As for drug Imipenem-Cilastatin (Merck Sharp & Dohme Corp U.S.A.), sensitivity and predictive value negative and is 93.1% 78.7% respectively. And 88.2% and 68.5% respectively.